Background/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases were searched to identify abstracts for randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC from inception to the end of April 2016. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated. Results: Ten eligible papers reporting six RCTs were included. In the network meta-analysis of patients with RAS mutations, bevacizumab + chemotherapy prolonged PFS compared with chemotherapy alone (HR 0.75, 95% CI 0.51-1.10), but the difference was not statistically significant. Bevacizumab + chemotherapy did not prolong OS compared with chemotherapy alone (HR 1.10, 95% CI 0.73-1.66). Conclusion: There was insufficient evidence to definitively state that patients with RAS mutations mCRC could benefit from bevacizumab combined with chemotherapy as first-line treatment.
Introduction
It has been reported that patients with RAS mutations metastatic colorectal cancer (mCRC) have poor prognosis than patients without RAS mutations [1] . Additionally, it has been shown that RAS mutations are negative predictive factors for first-line treatment with an anti-epidermal growth factor receptor (EGFR) combined with chemotherapy [2] [3] [4] .
Anti-angiogenic treatment is another strategy for the treatment of mCRC. Bevacizumab is a humanized monoclonal antibody (moAb) that can bind to vascular endothelial growth factor (VEGF), and it is currently the most frequently used anti-VEGF moAb [5, 6] . Nowadays, bevacizumab is used in most of the patients with mCRC without previously testing for RAS status [7] [8] [9] . In a previous study, the median overall survival (OS) of patients with mCRC treated with chemotherapy alone was 13.6-20.7 months [2] [3] [4] [9] [10] [11] [12] . But the median OS of patients with mCRC treated with bevacizumab combined with chemotherapy, without previous assessment of RAS mutations, was 19.9-20.6 months [7] [8] [9] 13] .
Results of published studies suggest that the addition of bevacizumab to chemotherapy as first-line treatment improved treatment efficacy and OS of patients with mCRC [7] [8] [9] . Reportedly, the median OS of patients with RAS wild-type mCRC was longer than that of patients with RAS mutations [2-4, 7, 8] . However, it remains uncertainwhether patients with RAS mutations can obtain clinical benefits from the addition of bevacizumab to chemotherapy. This network meta-analysis aimed to assess the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC.
Materials and Methods

Search strategy
This systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [14] . We searched for abstracts of randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC in PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases from inception to the end of April 2016. The bibliographies of included trials and related reviews were revised to identify potential articles, which were searched for manually. In this network meta-analysis, trials that compared two or more first-line treatment strategies of patients with RAS mutations mCRC were included.
Pubmed 
Data extraction and assessment for risk of bias
The full manuscripts of eligible studies were reviewed independently by two investigators (Z-MY, Y-P). Information was extracted and inserted into an electronic database, including patient characteristics, inclusion and exclusion criteria, treatment protocols, and outcomes. Any disagreement between reviewers was discussed with other coauthors and corresponding author until a consensus was reached.
Data synthesis and analysis
The outcomes analyzed in this network meta-analysis included progression-free survival (PFS) and OS. Random-effects models were used to account for the heterogeneity among studies.
Traditional meta-analysis was performed using Stata 12.1 (StataCorp, College Station, TX, USA). Network meta-analysis was performed using a netmeta package developed according to the theories of a classical frequentist setting under R language framework.
Results
The title and abstract of 168 studies were reviewed. After the initial screening, we performed a detailed assessment of potentially eligible papers. Finally, 10 papers reporting six RCTs were included (Fig. 1) . Table 1 showed the characteristics of these six RCTs. A total of 1,465 patients with mCRC and RAS mutations, receiving first-line treatment, were enrolledand randomized into two groups (treatment vs control), respectively (Table 1) . Methodological quality assessment was performed according to the latest guidelines in the Cochrane Handbook for Systematic Reviews of Interventions. The quality of the included studies was high ( Table 2) .
The network of all the comparisons analyzed is shown in Fig.  2 . A total of three regimens from six trails were included in the network. Three studies compared anti-EGFR + chemotherapy and chemotherapy alone. Two studies compared anti-EGFR + chemotherapy and bevacizumab + chemotherapy. One study compared bevacizumab + chemotherapy and chemotherapy alone.
In three studies, PFS was reported as the primary end point (PRIME, CRYSTAL, PEAK) [3, 4, 8, 10, 12] , and in three other studies, as the secondary end point (FIRE3, OPUS, AVF2107) [2, 7, 9, 11, 13] . In all included studies, OS was reported as the secondary end point [2] [3] [4] [7] [8] [9] [10] [11] [12] [13] . The results of direct comparisons are shown (Fig. 5) .
Discussion
This network meta-analysis compared the efficacy of chemotherapy in combination with bevacizumab or anti-EGFR moAb to chemotherapy in patients with RAS mutations mCRC (N = 1,465). The present results suggest that evidence is insufficient to definitively state that bevacizumab + chemotherapy would not provide any advantage to patients with RAS mutations over anti-EGFR moAb or chemotherapy alone.
In the network meta-analysis of patients with RAS mutations, bevacizumab + chemotherapy prolonged PFS compared with chemotherapy alone and anti-EGFR + chemotherapy, but the difference was not statistically significant. Both bevacizumab + chemotherapy and anti-EGFR + chemotherapy experienced did not prolong OS of patients with RAS mutations compared with chemotherapy alone. Several reasons could explain the benefit of bevacizumab + chemotherapy in terms of PFS rather than OS. First, the primary end points of most involved RCTs included PFS rather than OS. Further, PFS reflects the effectiveness of the first-line therapy. Thus, PFS might be a more appropriate primary end point for the first-line treatment of mCRC. Second, OS was likely to be influenced by multiple factors, including subsequent treatments. Third, the sample size of patients with RAS mutations was still overly small for the difference to reach statistical significance.
Results of several clinical trials indicated that all patients without RAS status testing may benefit from the combination of bevacizumab and chemotherapy. The AVF2107 study was the first phase III study to suggest that the efficacy of the anti-VEGF moAb bevacizumab in the first-line treatment of mCRC was independent of KRAS status, unlike anti-EGFR moAb [9] . In 2008, the No. 16966 trial, a randomized phase III study, evaluated the efficacy of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line treatment for mCRC without previously testing for RAS status. The No. 16966 trial suggested that the addition of bevacizumab improved PFS of patients, but the difference did not reach statistical significance [15] . The FIRE3 study was the first head-to-head randomized phase III clinical trial to compare the efficacy of bevacizumab and anti-EGFR moAb in combination with an irinotecan-containing regimen for the first-line treatment of mCRC. The FIRE3 study suggested that there was no difference of efficacy between bevacizumab + chemotherapy and anti-EGFR moAb + chemotherapy for patients with RAS mutations [7] . These results were consistent with the result of our network meta-analysis. However, the results of the PEAK study were inconsistent with this trend. The PEAK study was the first head-to-head randomized phase II clinical trial to compare the efficacy of bevacizumab and anti-EGFR moAb in combination with an oxaliplatin-containing regimen for the first-line treatment of mCRC. The PEAK study suggested that the addition of bevacizumab in an oxaliplatincontaining regimen resulted in a better PFS but worse OS in patientswith RAS mutations [8] .
The resulting improved OS in the anti-EGFR moAb arm was explained by the high percentage of patients that received subsequent chemotherapy and anti-VEGF treatment in this arm. Because the OS curves in these studies separated after approximately 2 years, it seemsthat thefollowing treatment contributed to the OS difference. Additionally, only 51 patients with other RAS mutations were enrolled in the PEAK study. Moreover, significant heterogeneity may exist between this phase II study and other phase III studies. The median OS of patients with RAS mutations that received anti-EGFR combined with chemotherapy was 27 months in the PEAK study, but it ranged from 13.5 to 20.3 months in other studies. Furthermore, the CALGB 80405 study was another head-to-head randomized phase III clinical trial that compared whether there was a clinical benefit of adding bevacizumab or anti-EGFR moAb to chemotherapy. However, the data for treatment outcomes of patients with RAS mutations in the CALGB 80405 study have not been published yet.
In 2010, Loupakis et al. published a meta-analysis that included the AVF2107 and No.16966 trials, along with two other studies, and aimed to analyze the benefit of adding bevacizumab to chemotherapy as first-line treatment for mCRC [16] . They suggested that the addition of bevacizumab prolonged both PFS and OS by 17.1% and 8.6%, respectively. The studies involved in this meta-analysis included phase II and III clinical trials. Of note, RAS status was not evaluated in that meta-analysis. As far as we know, no previous meta-analyses aimed to compare the benefit of bevacizumab and anti-EGFR combined with chemotherapy as first-line treatment for mCRC. This network meta-analysis is the first to assess the clinical benefit of bevacizumab combined with chemotherapy, anti-EGFR combined with chemotherapy and chemotherapy alone for the first-line treatment of patients with RAS mutations mCRC.
Petrelli et al. published a meta-analysis in 2015 that aimed to find the predictors of clinical outcome of bevacizumab in combination with chemotherapy for the first-line treatment of mCRC [17] . They suggested that mCRC with KRAS mutations have high risk of death compared with patients with KRAS wild-type. This conclusion was drawn based on the pooled HRs of three studies. All patients in these three studies were treated with bevacizumab in combination with chemotherapy. Patients were stratified by KRAS status. Median OS was 17.98 months in patients with KRAS mutations and 26.73 months in patients without KRAS mutations.
Our network meta-analysis had several strengths. This study was the first comprehensive comparative study of all the present major strategies for the first-line treatment of patients with RAS mutations mCRC. Both PFS and OS were assessed in both a traditional meta-analysis and a network meta-analysis. The traditional meta-analysis performed a direct comparison between the two strategies, with little heterogeneity. However, only the AVF2107 study compared bevacizumab + chemotherapy with chemotherapy alone among the patients with
